The ketolide antibiotic ABT-773 is a specific inhibitor of translation and 50S ribosomal subunit formation in Streptococcus pneumoniae cells

被引:18
作者
Champney, WS [1 ]
Pelt, J [1 ]
机构
[1] E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA
关键词
D O I
10.1007/s00284-001-0110-9
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
ABT-773 is a new 3-keto macrolide antibiotic that has been shown to be very effective against infections by Gram-positive microorganisms. This work examines its inhibitory effects in cells of Streptococcus pneumoniae. ABT-773 caused a proportional decline in cell growth rates and viability with an IC50 of 5 ng/ml. Protein synthesis in these cells was reduced by 50% at an antibiotic concentration of 2.5 ng/ml. This compound was also found to be a very effective inhibitor of the formation of the 50S ribosomal subunit in growing cells. Pulse and chase labeling assays revealed a reduced rate of 50S synthesis in antibiotic-treated cells. At 2 ng/ml, the rate was reduced to 33% of the control synthesis rate. An IC50 of 5 ng/ml was found for the effect on this process, indicating an equal effect of the drug on translation and assembly. Synthesis of the 30S ribosomal subunit was unaffected by this antibiotic. The effects of ABT-773 in S. pneumoniae are compared with those of the related ketolide antibiotic telithromycin in S. pneumoniae and in Staphylococcus aureus.
引用
收藏
页码:155 / 160
页数:6
相关论文
共 41 条
[1]  
AMABILECUEVAS CF, 1995, AM SCI, V83, P320
[2]   The in vitro activity of ABT773, a new ketolide antimicrobial agent [J].
Andrews, JM ;
Weller, TMA ;
Ashby, JP ;
Walker, RM ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (06) :1017-1022
[3]   ANTIMICROBIAL RESISTANCE IN STREPTOCOCCUS-PNEUMONIAE - AN OVERVIEW [J].
APPELBAUM, PC .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (01) :77-83
[4]   Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin) [J].
Barry, AL ;
Fuchs, PC ;
Brown, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) :945-946
[5]   Ketolides lack inducibility properties of MLSB resistance phenotype [J].
Bonnefoy, A ;
Girard, AM ;
Agouridas, C ;
Chantot, JF .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) :85-90
[6]   The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent [J].
Boswell, FJ ;
Andrews, JM ;
Ashby, JP ;
Fogarty, C ;
Brenwald, NP ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (06) :703-709
[7]   In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [J].
Brueggemann, AB ;
Doern, GV ;
Huynh, HK ;
Wingert, EM ;
Rhomberg, PR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :447-449
[8]  
Bryskier A, 1997, INFEC DIS T, V21, P39
[9]   Studies of the novel ketolide ABT-773:: Transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae [J].
Capobianco, JO ;
Cao, ZS ;
Shortridge, VD ;
Ma, ZK ;
Flamm, RK ;
Zhong, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) :1562-1567
[10]  
Champney W. S., 2001, Current Drug Targets - Infectious Disorders, V1, P19, DOI 10.2174/1568005013343281